810nm激光睫状体光凝治疗难治性青光眼的疗效
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Effect observation of 810nm laser cyclophotocoagulation for refractory glaucoma
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:探讨810nm激光经巩膜睫状体光凝治疗难治性青光眼的临床疗效。

    方法:对25例30眼难治性青光眼患者行810nm激光经巩膜睫状体光凝术,术后随访3mo,分析术后眼压、疼痛感、视力、并发症等情况。

    结果:术后随访期间全部患者眼痛症状均缓解。术前平均眼压为50.42±2.50mmHg,末次随访时平均眼压15.95±4.19mmHg,术后眼压与术前相比,差异有显著统计学意义(P<0.01)。光凝术后2眼(6.7%)视力提高,24眼(80.0%)视力无变化,4眼(13.3%)视力下降。术后前房渗出12眼(40.0%),前房积血3眼(10.0%),玻璃体积血1眼(3.3%),药物治疗后消失。

    结论:810nm激光经巩膜睫状体光凝术是治疗难治性青光眼的有效方法,能显著降低眼压,减少患者痛苦,并发症少。

    Abstract:

    AIM: To investigate the therapeutic effects of transscleral cyclophotocoagulation procedures(TCP)with 810nm laser for refractory glaucoma.

    METHODS: Totally 25 patients(30 eyes)with refractory glaucoma were treated with TCP. The follow-up time was 3 months, the patients' symptom, intraocular pressure(IOP), visual acuity and complications were analyzed.

    RESULTS: During the follow-up period, all patients' ocular pain was reduced. The mean IOP before TCP and at the last follow-up time were(50.42±2.50)mmHg(1kPa=7.5mmHg)and(15. 95±4.19)mmHg, respectively, the IOP decreased after TCP, there was significant difference(P<0.001). After TCP, the visual acuity improved in 2 eyes(6.7%), had no change in 24 eyes(80.0%), decreased in 4 eyes(13.3%). After TCP, the exudation of anterior chamber appeared in 12 eyes(40.0%), hyphema of anterior chamber appeared in 3 eyes(10.0%), vitreous hemorrhage in 1 eye(3.3%), which were all cured after drug treatment.

    CONCLUSION: TCP with 810nm laser in treatment of refractory glaucoma has curative effect, can degrade the IOP, lessen ocular pain and with few complications.

    参考文献
    相似文献
    引证文献
引用本文

底煜,归东海,聂庆珠,等.810nm激光睫状体光凝治疗难治性青光眼的疗效.国际眼科杂志, 2013,13(3):515-516.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2012-11-26
  • 最后修改日期:2013-02-26
  • 录用日期:
  • 在线发布日期:
  • 出版日期: